Loading...
Market
Next major milestone for Mitapivat in thalassemia treatment by end of 2024?
5
Resolution / Starting Odds
FDA approval • 25%
EMA approval • 25%
Both approvals • 25%
No approvals • 25%
Agios Pharmaceuticals official announcements
Story
$AGIO: Agios Pharmaceuticals Announces Positive Phase 3 Results for Mitapivat in Thalassemia, 30.4% vs. 12.6%
Jun 3, 2024, 10:34 AM
Agios Pharmaceuticals ($AGIO) has announced that its Phase 3 ENERGIZE-T study of Mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia met its primary endpoint and all key secondary endpoints. The study demonstrated a significant transfusion reduction response, with 30.4% of participants showing improvement compared to 12.6% in the placebo group. This positive outcome, announced on June 3, 2024, marks a potential novel advancement in care for patients with this inherited blood disorder.
View original story
Similar markets
FDA approval • 33%
EMA approval • 33%
No major milestone • 33%
Phase III trial in the US • 25%
Approval in China • 25%
Approval in the EU • 25%
Partnership with another pharmaceutical company • 25%
FDA approval for another drug • 33%
Major partnership announcement • 33%
No major milestone • 33%
No new approvals • 25%
1 new approval • 25%
2 new approvals • 25%
3 or more new approvals • 25%